Brilaroxazine hydrochloride is under clinical development by Reviva Pharmaceuticals and currently in Phase I for Major Depressive Disorder.

Neumora Therapeutics to release phase 3 data on Navacaprant for MDD treatment in 2024. Check out NMRA's catalysts that might ...

Major depressive disorder (MDD) is a chronic and recurrent ... of such MDD patients remit following adequate antidepressant treatment, while most MDD patients suffer from significant core ...

The changing landscape of health care during COVID-19 placed focus on increasing accessibility to mental health resources other than the emergency department (ED), with potential savings of over $ ...

Nelivaptan (NB-415, SSR-149415) is under development for the treatment of depression including major depressive disorder (MDD). The drug candidate targets vasopressin receptor 1B ( (V1bR). It is ...

Current treatments are estimated to only reduce about one-third of the disease burden of depressive disorders. Prevention may be an alternative strategy to further reduce the disease burden of ...

People explore different treatments and therapies to help with depression, and recently, researchers wanted to understand if ...

The following is a summary of “Service coverage for major depressive disorder: estimated rates of minimally adequate ...

White matter alterations within the brain are associated with cognitive impairment among individuals with and without major ...

TMS has been approved for treating clinical depression in adults since 2008. Recent effectiveness data with adolescents shows ...

A groundbreaking clinical trial has revealed that nerve-stimulating therapy can bring significant improvements to people with ...